Dehydroxymethylepoxyquinomicin(DHMEQ), a novel NF-kappaB inhibitor, inhibits allergic inflammation and airway remodeling in murine models of asthma

点击翻译按钮获取中文摘要

DHMEQ significantly reduced eosinophilic airway inflammation and levels of Th2 cytokines in bronchoalveolar lavage fluid in murine asthma model. It also inhibited parameters of airway remodeling including mucus production, peribronchial fibrosis and the expression ofα-smooth muscle actin. These results indicate that DHMEQ inhibits allergic airway inflammation and airway remodeling in murine models of asthma. DHMEQ may have therapeutic potential in the treatment of asthma.